Biochemical properties of indoleamine 2,3-dioxygenase: From structure to optimized design of inhibitors

Current Medicinal Chemistry

Volumn 18, Issue 15, 2011, Pages 2205-2214

  Lancellotti, S ^a   Novarese, L ^a   De Cristofaro, R ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Immune tolerance; Indoleamine 2,3 dioxygenase; X ray structure of oxygenases

Indexed keywords

1 METHYL TRYPTOPHAN; 4 PHENYLIMIDAZOLE; 5 BROMO BRASSININ; BENZOTHIAZOLE DERIVATIVE; BETA CARBOLINE; BRASSININ; CYTOCHROME B5; ENZYME INHIBITOR; EXIGUAMINE A; FERRIC ION; FERROUS ION; HEME; IMMUNOMODULATING AGENT; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; KYNURENINE; METHYL THIOHYDANTOIN TRYPTOPHAN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NICOTINIC RECEPTOR BLOCKING AGENT; OXYGEN; OXYGENASE; PACLITAXEL; THIAZOLE DERIVATIVE; TRIAZOLE DERIVATIVE; TRYPTOPHAN; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; ARTICLE; CATALYSIS; CELL DIFFERENTIATION; CENTRAL NERVOUS SYSTEM; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG POTENCY; DRUG STRUCTURE; ELECTRON; ENZYME ACTIVE SITE; ENZYME INHIBITION; HUMAN; IC 50; IMMUNE RESPONSE; IMMUNOTHERAPY; INFLAMMATION; IRON BINDING CAPACITY; LYMPHOCYTE FUNCTION; NONHUMAN; PROTEIN DOMAIN; REGULATORY T LYMPHOCYTE; SITE DIRECTED MUTAGENESIS; THERMODYNAMICS; X RAY DIFFRACTION;

EID: 79957961707     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711795656108     Document Type: Article

References (93)

1. Nadkarni, S.; Mauri, C.; Ehrenstein, M.R. Anti-TNF-α?therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-β J. Exp. Med., 2007, 204(1), 33-39. (Pubitemid 46148753)
2. Fallarino, F.; Grohmann, U.; Vacca, C.; Bianchi, R.; Orabona, C.; Spreca, A.; Fioretti, M.C.; Puccetti, P. T cell apoptosis by tryptophan catabolism. Cell Death Differ, 2002, 9(10), 1069-1077.
3. Munn, D.H.; Zhou, M.; Attwood, J.T.; Bondarev, I.; Conway, S.J.; Marshall, B.; Brown, C.; Mellor, A.L. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science, 1998, 281(5380), 1191-1193. (Pubitemid 28406294)
4. Munn, D.H.; Mellor, A.L. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest., 2007, 117(5), 1147-1154. (Pubitemid 46718399)
5. Rutella, S.; Bonanno, G.; De Cristofaro, R. Targeting indoleamine 2,3- dioxygenase (IDO) to counteract tumour-induced immune dysfunction: from biochemistry to clinical development. Endocr Metab Immune Disord Drug Targets, 2009, 9(2), 151-177.
6. Uyttenhove, C.; Pilotte, L.; Theate, I.; Stroobant, V.; Colau, D.; Parmentier, N.; Boon, T.; Van den Eynde, B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3- dioxygenase. Nat. Med., 2003, 9(10), 1269-1274. (Pubitemid 37279849)
7. Mellor, A.L.; Munn, D.H. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol., 2004, 4(10), 762-774. (Pubitemid 39336293)
8. Arefayene, M.; Mamidipalli, S.; Philips, S.; Cao, D.; Flockhart, D.; Wilkes, D.; Skaar, T. Identification of functional genetic variants of the indoleamine 2,3 dioxygenase gene. AACR Meeting Abstracts, 2006, April 1(1), 1119.
9. Braun, D.; Longman, R.S.; Albert, M.L. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood, 2005, 106(7), 2375-2381. (Pubitemid 41510810)
10. Ball, H.J.; Yuasa, H.J.; Austin, C.J.; Weiser, S.; Hunt, N.H. Indoleamine 2,3- dioxygenase-2; a new enzyme in the kynurenine pathway. Int J Biochem Cell Biol, 2008.
11. Ball, H.J.; Sanchez-Perez, A.; Weiser, S.; Austin, C.J.; Astelbauer, F.; Miu, J.; McQuillan, J.A.; Stocker, R.; Jermiin, L.S.; Hunt, N.H. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene, 2007, 396(1), 203-213. (Pubitemid 46818792)
12. Metz, R.; Duhadaway, J.B.; Kamasani, U.; Laury-Kleintop, L.; Muller, A.J.; Prendergast, G.C. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res, 2007, 67(15), 7082-7087. (Pubitemid 47206533)
13. Lob, S.; Konigsrainer, A.; Schafer, R.; Rammensee, H.G.; Opelz, G.; Terness, P. Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood, 2008, 111(4), 2152-2154. (Pubitemid 351451527)
14. Katz, J.B.; Muller, A.J.; Prendergast, G.C. Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol. Rev., 2008, 222(1), 206-221. (Pubitemid 351430372)
15. Yoshida, R.; Urade, Y.; Tokuda, M.; Hayaishi, O. Induction of indoleamine 2,3-dioxygenase in mouse lung during virus infection. Proc. Natl. Acad. Sci. U. S. A., 1979, 76(8), 4084-4086. (Pubitemid 9249028)
16. Yamazaki, F.; Kuroiwa, T.; Takikawa, O.; Kido, R. Human indolylamine 2,3-dioxygenase. Its tissue distribution, and characterization of the placental enzyme. Biochem J, 1985, 230(3), 635-638. (Pubitemid 16236320)
17. Munn, D.H.; Shafizadeh, E.; Attwood, J.T.; Bondarev, I.; Pashine, A.; Mellor, A.L. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med., 1999, 189(9), 1363-1372. (Pubitemid 29227522)
18. Forrest, C.M.; Gould, S.R.; Darlington, L.G.; Stone, T.W. Levels of purine, kynurenine and lipid peroxidation products in patients with inflammatory bowel disease. Adv Exp Med Biol, 2003, 527, 395-400. (Pubitemid 38197667)
19. Forrest, C.M.; Kennedy, A.; Stone, T.W.; Stoy, N.; Darlington, L.G. Kynurenine and neopterin levels in patients with rheumatoid arthritis and osteoporosis during drug treatment. Adv Exp Med Biol, 2003, 527, 287-295. (Pubitemid 38197654)
20. Daubener, W.; Schmidt, S.K.; Heseler, K.; Spekker, K.H.; MacKenzie, C.R. Antimicrobial and immunoregulatory effector mechanisms in human endothelial cells. Indoleamine 2,3-dioxygenase versus inducible nitric oxide synthase. Thromb Haemost, 2009, 102(6), 1110-1116.
21. Njau, F.; Geffers, R.; Thalmann, J.; Haller, H.; Wagner, A.D. Restriction of Chlamydia pneumoniae replication in human dendritic cell by activation of indoleamine 2,3-dioxygenase. Microbes Infect, 2009, 11(13), 1002-1010.
22. Thomas, S.R.; Stocker, R. Redox reactions related to indoleamine 2,3- dioxygenase and tryptophan metabolism along the kynurenine pathway. Redox Rep, 1999, 4(5), 199-220. (Pubitemid 30088218)
23. Frumento, G.; Rotondo, R.; Tonetti, M.; Damonte, G.; Benatti, U.; Ferrara, G.B. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med., 2002, 196(4), 459-468.
24. Schwarcz, R.; Whetsell, W.O. Jr.; Mangano, R.M. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science, 1983, 219(4582), 316-318. (Pubitemid 13222319)
25. Heyes, M.P.; Rubinow, D.; Lane, C.; Markey, S.P. Cerebrospinal fluid quinolinic acid concentrations are increased in acquired immune deficiency syndrome. Ann Neurol, 1989, 26(2), 275-277. (Pubitemid 19193098)
26. Medana, I.M.; Day, N.P.; Salahifar-Sabet, H.; Stocker, R.; Smythe, G.; Bwanaisa, L.; Njobvu, A.; Kayira, K.; Turner, G.D.; Taylor, T.E.; Hunt, N.H. Metabolites of the kynurenine pathway of tryptophan metabolism in the cerebrospinal fluid of Malawian children with malaria. J Infect Dis, 2003, 188(6), 844-849. (Pubitemid 37176030)
27. Guillemin, G.J.; Brew, B.J.; Noonan, C.E.; Takikawa, O.; Cullen, K.M. Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol Appl Neurobiol, 2005, 31(4), 395-404. (Pubitemid 41059860)
28. Ozaki, Y.; Edelstein, M.P.; Duch, D.S. Induction of indoleamine 2,3- dioxygenase: a mechanism of the antitumor activity of interferon gamma. Proc Natl Acad Sci U S A, 1988, 85(4), 1242-1246. (Pubitemid 18073985)
29. Feder-Mengus, C.; Wyler, S.; Hudolin, T.; Ruszat, R.; Bubendorf, L.; Chiarugi, A.; Pittelli, M.; Weber, W.P.; Bachmann, A.; Gasser, T.C.; Sulser, T.; Heberer, M.; Spagnoli, G.C.; Provenzano, M. High expression of indoleamine 2,3-dioxygenase gene in prostate cancer. Eur J Cancer, 2008, 44(15), 2266-2275.
30. Riesenberg, R.; Weiler, C.; Spring, O.; Eder, M.; Buchner, A.; Popp, T.; Castro, M.; Kammerer, R.; Takikawa, O.; Hatz, R.A.; Stief, C.G.; Hofstetter, A.; Zimmermann, W. Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin. Cancer Res., 2007, 13(23), 6993-7002. (Pubitemid 350276880)
31. Sakamuro, D.; Elliott, K.J.; Wechsler-Reya, R.; Prendergast, G.C. BIN1 is a novel MYC-interacting protein with features of a tumour suppressor. Nat Genet, 1996, 14(1), 69-77. (Pubitemid 26301549)
32. Kerangueven, F.; Noguchi, T.; Coulier, F.; Allione, F.; Wargniez, V.; Simony-Lafontaine, J.; Longy, M.; Jacquemier, J.; Sobol, H.; Eisinger, F.; Birnbaum, D. Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas. Cancer Res, 1997, 57(24), 5469-5474. (Pubitemid 28006749)
33. Muller, A.J.; Baker, J.F.; DuHadaway, J.B.; Ge, K.; Farmer, G.; Donover, P.S.; Meade, R.; Reid, C.; Grzanna, R.; Roach, A.H.; Shah, N.; Soler, A.P.; Prendergast, G.C. Targeted disruption of the murine Bin1/Amphiphysin IIgene does not disable endocytosis but results in embryonic cardiomyopathy with aberrant myofibril formation. Mol Cell Biol, 2003, 23(12), 4295-4306. (Pubitemid 36666431)
34. Wechsler-Reya, R.; Sakamuro, D.; Zhang, J.; Duhadaway, J.; Prendergast, G.C. Structural analysis of the human BIN1 gene. Evidence for tissuespecific transcriptional regulation and alternate RNA splicing. J. Biol. Chem., 1997, 272(50), 31453-31458. (Pubitemid 28013284)
35. Prendergast, G.C. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene, 2008, 27(28), 3889-3900. (Pubitemid 351913639)
36. Kuznetsova, E.B.; Kekeeva, T.V.; Larin, S.S.; Zemlyakova, V.V.; Khomyakova, A.V.; Babenko, O.V.; Nemtsova, M.V.; Zaletayev, D.V.; Strelnikov, V.V. Methylation of the BIN1 gene promoter CpG island associated with breast and prostate cancer. J Carcinog, 2007, 6, 9-14.
37. Muller, A.J.; DuHadaway, J.B.; Donover, P.S.; Sutanto-Ward, E.; Prendergast, G.C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med., 2005, 11(3), 312-319. (Pubitemid 40460560)
38. Chang, M.Y.; Boulden, J.; Sutanto-Ward, E.; Duhadaway, J.B.; Soler, A.P.; Muller, A.J.; Prendergast, G.C. Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression. Cancer Res, 2007, 67(1), 100-107. (Pubitemid 46142764)
39. Dai, W.; Gupta, S.L. Regulation of indoleamine 2,3-dioxygenase gene expression in human fibroblasts by interferon-gamma. Upstream control region discriminates between interferon-gamma and interferon-alpha. J Biol Chem, 1990, 265(32), 19871-19877. (Pubitemid 120013943)
40. Babcock, T.A.; Carlin, J.M. Transcriptional activation of indoleamine dioxygenase by interleukin 1 and tumor necrosis factor alpha in interferontreated epithelial cells. Cytokine, 2000, 12(6), 588-594. (Pubitemid 30453486)
41. Hissong, B.D.; Byrne, G.I.; Padilla, M.L.; Carlin, J.M. Upregulation of interferon-induced indoleamine 2,3-dioxygenase in human macrophage cultures by lipopolysaccharide, muramyl tripeptide, and interleukin-1. Cell Immunol, 1995, 160(2), 264-269.
42. Galimi, F.; Cottone, E.; Vigna, E.; Arena, N.; Boccaccio, C.; Giordano, S.; Naldini, L.; Comoglio, P.M. Hepatocyte growth factor is a regulator of monocyte-macrophage function. J. Immunol., 2001, 166(2), 1241-1247. (Pubitemid 32060285)
43. Rutella, S.; Bonanno, G.; Procoli, A.; Mariotti, A.; de Ritis, D.G.; Curti, A.; Danese, S.; Pessina, G.; Pandolfi, S.; Natoni, F.; Di Febo, A.; Scambia, G.; Manfredini, R.; Salati, S.; Ferrari, S.; Pierelli, L.; Leone, G.; Lemoli, R.M. Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features. Blood, 2006, 108(1), 218-227. (Pubitemid 43990632)
44. Sugimoto, H.; Oda, S.; Otsuki, T.; Hino, T.; Yoshida, T.; Shiro, Y. Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. Proc. Natl. Acad. Sci. U. S. A., 2006, 103(8), 2611-2616.
45. Hu, B.; Hissong, B.D.; Carlin, J.M. Interleukin-1 enhances indoleamine 2,3- dioxygenase activity by increasing specific mRNA expression in human mononuclear phagocytes. J. Interferon Cytokine Res., 1995, 15(7), 617-624.
46. Littlejohn, T.K.; Takikawa, O.; Truscott, R.J.; Walker, M.J. Asp274 and his346 are essential for heme binding and catalytic function of human indoleamine 2,3-dioxygenase. J. Biol. Chem., 2003, 278(32), 29525-29531. (Pubitemid 36962333)
47. Terentis, A.C.; Thomas, S.R.; Takikawa, O.; Littlejohn, T.K.; Truscott, R.J.; Armstrong, R.S.; Yeh, S.R.; Stocker, R. The heme environment of recombinant human indoleamine 2,3-dioxygenase. Structural properties and substrate-ligand interactions. J. Biol. Chem., 2002, 277(18), 15788-15794. (Pubitemid 34967855)
48. Papadopoulou, N.D.; Mewies, M.; McLean, K.J.; Seward, H.E.; Svistunenko, D.A.; Munro, A.W.; Raven, E.L. Redox and spectroscopic properties of human indoleamine 2,3-dioxygenase and a His303Ala variant: implications for catalysis. Biochemistry, 2005, 44(43), 14318-14328. (Pubitemid 41533056)
49. Macchiarulo, A.; Nuti, R.; Bellocchi, D.; Camaioni, E.; Pellicciari, R. Molecular docking and spatial coarse graining simulations as tools to investigate substrate recognition, enhancer binding and conformational transitions in indoleamine-2,3-dioxygenase (IDO). Biochim Biophys Acta, 2007, 1774(8), 1058-1068. (Pubitemid 47176959)
50. Ribeiro, C.A.; Grando, V.; Dutra Filho, C.S.; Wannmacher, C.M.; Wajner, M. Evidence that quinolinic acid severely impairs energy metabolism through activation of NMDA receptors in striatum from developing rats. J Neurochem, 2006, 99(6), 1531-1542. (Pubitemid 44924231)
51. Stone, T.W. Kynurenic acid blocks nicotinic synaptic transmission to hippocampal interneurons in young rats. Eur J Neurosci, 2007, 25(9), 2656-2665. (Pubitemid 46888851)
52. Stone, T.W.; Darlington, L.G. Endogenous kynurenines as targets for drug discovery and development. Nat. Rev. Drug Discov., 2002, 1(8), 609-620. (Pubitemid 37361524)
53. Hilmas, C.; Pereira, E.F.; Alkondon, M.; Rassoulpour, A.; Schwarcz, R.; Albuquerque, E.X. The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases non-α7 nicotinic receptor expression: physiopathological implications. J Neurosci, 2001, 21(19), 7463-7473. (Pubitemid 32904945)
54. Chauhan, N.; Basran, J.; Efimov, I.; Svistunenko, D.A.; Seward, H.E.; Moody, P.C.; Raven, E.L. The Role of Serine 167 in Human Indoleamine 2,3-Dioxygenase: A Comparison with Tryptophan 2,3-Dioxygenase. Biochemistry, 2008.
55. Hirata, F.; Ohnishi, T.; Hayaishi, O. Indoleamine 2,3-dioxygenase. Characterization and properties of enzyme. O2- complex. J. Biol. Chem., 1977, 252(13), 4637-4642. (Pubitemid 8155985)
56. Takikawa, O. Biochemical and medical aspects of the indoleamine 2,3- dioxygenase-initiated L-tryptophan metabolism. Biochem. Biophys. Res. Commun., 2005, 338(1), 12-19. (Pubitemid 41540531)
57. Vottero, E.; Mitchell, D.A.; Page, M.J.; MacGillivray, R.T.; Sadowski, I.J.; Roberge, M.; Mauk, A.G. Cytochrome b(5) is a major reductant in vivo of human indoleamine 2,3-dioxygenase expressed in yeast. FEBS Lett, 2006, 580(9), 2265-2268.
58. Maghzal, G.J.; Thomas, S.R.; Hunt, N.H.; Stocker, R. Cytochrome b5, not superoxide anion radical, is a major reductant of indoleamine 2,3- dioxygenase in human cells. J Biol Chem, 2008, 283(18), 12014-12025.
59. Ohnishi, T.; Hirata, F.; Hayaish, O. Indoleamine 2,3-dioxygenase. Potassium superoxide as substrate. J. Biol. Chem., 1977, 252(13), 4643-4647. (Pubitemid 8155986)
60. Sono, M.; Roach, M.P.; Coulter, E.D.; Dawson, J.H. Heme-Containing Oxygenases. Chem Rev, 1996, 96(7), 2841-2888.
61. Cady, S.G.; Sono, M. 1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)- DLalanine (the oxygen analog of tryptophan), and [3-benzo(b)thienyl]-DLalanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch Biochem Biophys, 1991, 291(2), 326-333.
62. Fuchs, B.C.; Bode, B.P. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol, 2005, 15(4), 254-266. (Pubitemid 41065034)
63. Kudo, Y.; Boyd, C.A. The role of L-tryptophan transport in L-tryptophan degradation by indoleamine 2,3-dioxygenase in human placental explants. J. Physiol., 2001, 531(Pt 2), 417-423. (Pubitemid 32229667)
64. Shennan, D.B.; Thomson, J.; Barber, M.C.; Travers, M.T. Functional and molecular characteristics of system L in human breast cancer cells. Biochim Biophys Acta, 2003, 1611(1-2), 81-90. (Pubitemid 36351435)
65. Travers, M.T.; Gow, I.F.; Barber, M.C.; Thomson, J.; Shennan, D.B. Indoleamine 2,3-dioxygenase activity and L-tryptophan transport in human breast cancer cells. Biochim Biophys Acta, 2004, 1661(1), 106-112. (Pubitemid 38201576)
66. Seymour, R.L.; Ganapathy, V.; Mellor, A.L.; Munn, D.H. A high-affinity, tryptophan-selective amino acid transport system in human macrophages. J. Leukoc. Biol., 2006, 80(6), 1320-1327. (Pubitemid 44904970)
67. Kaper, T.; Looger, L.L.; Takanaga, H.; Platten, M.; Steinman, L.; Frommer, W.B. Nanosensor detection of an immunoregulatory tryptophan influx/kynurenine efflux cycle. PLoS Biol, 2007, 5(10), e257.
68. Hara, T.; Ogasawara, N.; Akimoto, H.; Takikawa, O.; Hiramatsu, R.; Kawabe, T.; Isobe, K.; Nagase, F. High-affinity uptake of kynurenine and nitric oxide-mediated inhibition of indoleamine 2,3-dioxygenase in bone marrow-derived myeloid dendritic cells. Immunol. Lett., 2008, 116(1), 95-102.
69. Watanabe, Y.; Fujiwara, M.; Hayaishi, O. 2,5-Dihydro-L-phenylalanine: a competitive inhibitor of indoleamine 2,3-dioxygenase. Biochem Biophys Res Commun, 1978, 85(1), 273-279. (Pubitemid 9073179)
70. Eguchi, N.; Watanabe, Y.; Kawanishi, K.; Hashimoto, Y.; Hayaishi, O. Inhibition of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase by beta-carboline and indole derivatives. Arch Biochem Biophys, 1984, 232(2), 602-609.
71. Sono, M.; Cady, S.G. Enzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2,3-dioxygenase. 1. Norharman and 4-phenylimidazole binding to the enzyme as inhibitors and heme ligands. Biochemistry, 1989, 28(13), 5392-5399. (Pubitemid 19175747)
72. Sono, M. Enzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2,3-dioxygenase. 2. Evidence for the existence of another binding site in the enzyme for indole derivative effectors. Biochemistry, 1989, 28(13), 5400-5407. (Pubitemid 19175748)
73. Di Pucchio, T.; Danese, S.; De Cristofaro, R.; Rutella, S. Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds. Expert Opin Ther Pat, 20(2), 229-250.
74. Muller, A.J.; Scherle, P.A. Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat. Rev. Cancer, 2006, 6(8), 613-625. (Pubitemid 44140859)
75. Hou, D.Y.; Muller, A.J.; Sharma, M.D.; DuHadaway, J.; Banerjee, T.; Johnson, M.; Mellor, A.L.; Prendergast, G.C.; Munn, D.H. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyltryptophan correlates with antitumor responses. Cancer Res, 2007, 67(2), 792-801. (Pubitemid 46192220)
76. Nakashima, H.; Uto, Y.; Nakata, E.; Nagasawa, H.; Ikkyu, K.; Hiraoka, N.; Nakashima, K.; Sasaki, Y.; Sugimoto, H.; Shiro, Y.; Hashimoto, T.; Okamoto, Y.; Asakawa, Y.; Hori, H. Synthesis and biological activity of 1- methyl-tryptophan-tirapazamine hybrids as hypoxia-targeting indoleamine 2,3-dioxygenase inhibitors. Bioorg Med Chem, 2008, 16(18), 8661-8669.
77. Yue, E.W.; Douty, B.; Wayland, B.; Bower, M.; Liu, X.; Leffet, L.; Wang, Q.; Bowman, K.J.; Hansbury, M.J.; Liu, C.; Wei, M.; Li, Y.; Wynn, R.; Burn, T.C.; Koblish, H.K.; Fridman, J.S.; Metcalf, B.; Scherle, P.A.; Combs, A.P. Discovery of potent competitive inhibitors of indoleamine 2,3- dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. J Med Chem, 2009, 52(23), 7364-7367.
78. Rohrig, U.F.; Awad, L.; Grosdidier, A.; Larrieu, P.; Stroobant, V.; Colau, D.; Cerundolo, V.; Simpson, A.J.; Vogel, P.; Van den Eynde, B.J.; Zoete, V.; Michielin, O. Rational Design of Indoleamine 2,3-Dioxygenase Inhibitors. J Med Chem.
79. Brastianos, H.C.; Vottero, E.; Patrick, B.O.; Van Soest, R.; Matainaho, T.; Mauk, A.G.; Andersen, R.J. Exiguamine A, an indoleamine-2,3-dioxygenase (IDO) inhibitor isolated from the marine sponge Neopetrosia exigua. J Am Chem Soc, 2006, 128(50), 16046-16047. (Pubitemid 44936592)
80. Pereira, A.; Vottero, E.; Roberge, M.; Mauk, A.G.; Andersen, R.J. Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata. J Nat Prod, 2006, 69(10), 1496-1499. (Pubitemid 44899767)
81. Banerjee, T.; Duhadaway, J.B.; Gaspari, P.; Sutanto-Ward, E.; Munn, D.H.; Mellor, A.L.; Malachowski, W.P.; Prendergast, G.C.; Muller, A.J. A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene, 2007, DOI 10.1038/sj.onc.1210939.
82. Jasperson, L.K.; Bucher, C.; Panoskaltsis-Mortari, A.; Taylor, P.A.; Mellor, A.L.; Munn, D.H.; Blazar, B.R. Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. Blood, 2008, 111(6), 3257-3265.
83. Gaspari, P.; Banerjee, T.; Malachowski, W.P.; Muller, A.J.; Prendergast, G.C.; DuHadaway, J.; Bennett, S.; Donovan, A.M. Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors. J. Med. Chem., 2006, 49(2), 684-692. (Pubitemid 43157498)
84. Banerjee, T.; Duhadaway, J.B.; Gaspari, P.; Sutanto-Ward, E.; Munn, D.H.; Mellor, A.L.; Malachowski, W.P.; Prendergast, G.C.; Muller, A.J. A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase. Oncogene, 2008, 27(20), 2851-2857. (Pubitemid 351620442)
85. Vottero, E.; Balgi, A.; Woods, K.; Tugendreich, S.; Melese, T.; Andersen, R.J.; Mauk, A.G.; Roberge, M. Inhibitors of human indoleamine 2,3- dioxygenase identified with a target-based screen in yeast. Biotechnol J, 2006, 1(3), 282-288.
86. Carr, G.; Chung, M.K.; Mauk, A.G.; Andersen, R.J. Synthesis of indoleamine 2,3-dioxygenase inhibitory analogues of the sponge alkaloid exiguamine A. J. Med. Chem., 2008, 51(9), 2634-2637. (Pubitemid 351620784)
87. Kumar, S.; Jaller, D.; Patel, B.; LaLonde, J.M.; DuHadaway, J.B.; Malachowski, W.P.; Prendergast, G.C.; Muller, A.J. Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3- dioxygenase. J. Med. Chem., 2008, 51(16), 4968-4977.
88. Muller, A.J.; Malachowski, W.P.; Prendergast, G.C. Indoleamine 2,3- dioxygenase in cancer: targeting pathological immune tolerance with smallmolecule inhibitors. Expert Opin Ther Targets, 2005, 9(4), 831-849. (Pubitemid 41131682)
89. Eguchi, N.; Watanabe, Y.; Kawanishi, K.; Hashimoto, Y.; Hayaishi, O. Inhibition of indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase by α-carboline and indole derivatives. Arch Biochem Biophys, 1984, 232(2), 602-609.
90. Kumar, S.; Malachowski, W.P.; Duhadaway, J.B.; Lalonde, J.M.; Carroll, P.J.; Jaller, D.; Metz, R.; Prendergast, G.C.; Muller, A.J. Indoleamine 2,3- dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. J. Med. Chem., 2008, 51(6), 1706-1718. (Pubitemid 351438852)
91. Rutella, S.; De Cristofaro, R.; Ferraccioli, G. Function and dysfunction of dendritic cells in autoimmune rheumatic diseases. Hum. Immunol., 2009, 70(5), 360-373.
92. Liu, L.; Liu, H.; Mah, C.; Fletcher, B.S. Indoleamine 2,3-dioxygenase attenuates inhibitor development in gene-therapy-treated hemophilia A mice. Gene Ther, 2009, 16(6), 724-733.
93. Bresalier, R.S.; Sandler, R.S.; Quan, H.; Bolognese, J.A.; Oxenius, B.; Horgan, K.; Lines, C.; Riddell, R.; Morton, D.; Lanas, A.; Konstam, M.A.; Baron, J.A. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med, 2005, 352(11), 1092-1102. (Pubitemid 40365350)